Assessing the evidence for remodelling of the airway in asthma.
Asthma is now described as being characterized by reversible airflow obstruction, with bronchial inflammation and tissue remodelling of the airway wall. The description of remodelling has been usefully invoked to account for a component of airflow obstruction that is unresponsive to usual bronchodilator therapy. It is crucial to examine critically the evidence for this view, particularly the quantitation of specific changes in the epithelium, mucus glands, cell infiltrate, collagen, vessels and smooth muscle of the bronchial wall. The useful tools of immunohistochemistry and molecular biology combined with airway biopsy and well-designed clinical trials will be essential to determine the specific roles of cells and cytokines in airway remodelling in asthma.
Wilson
J W
JW
Department of Respiratory Medicine, Monash Medical School and The Alfred Hospital, Commercial Rd, Prahran, 3181 Australia. john.wilson@med.monash.edu.au
Bamford
T L
TL
D000402:Airway Obstruction / Q000503:physiopathology*; D001249:Asthma / Q000453:epidemiology / Q000503:physiopathology*; D003094:Collagen; D016207:Cytokines / Q000494:pharmacology; D004487:Edema; D004804:Eosinophils; D004848:Epithelium / Q000473:pathology; D005347:Fibroblasts; D006133:Growth Substances / Q000494:pharmacology; D006801:Humans; D006984:Hypertrophy; D007150:Immunohistochemistry; D007249:Inflammation; D008264:Macrophages; D008407:Mast Cells; D009130:Muscle, Smooth / Q000473:pathology; D015995:Prevalence; D012137:Respiratory System / Q000033:anatomy & histology* / Q000276:immunology / Q000473:pathology; D012720:Severity of Illness Index; D013601:T-Lymphocytes
D016207:Cytokines; D006133:Growth Substances; D003094:Collagen